Navigation Links
Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness
Date:1/14/2014

rm the lives of patients and re-imagine the treatment of debilitating diseases. Spark's lead gene therapy candidate, for RPE65-related blindness, is currently in Phase 3 clinical trials with the potential to be the first approved gene therapy in the U.S., and the first in a series of therapies to address the significant unmet needs of patients living with blindness due to inherited retinal dystrophies.

Spark's founding team includes scientists who led the movement to develop gene therapy as a new treatment paradigm, establishing clinical proof of concept in the eye and liver and contributing key insights to the field that have resulted in a resurgence of industry interest in gene-based medicines. In addition to the Phase 3 program in RPE65-related blindness, the company has a Phase 1/2 program in hemophilia B, and preclinical programs to address neurodegenerative diseases and other inherited retinal dystrophies and hematologic disorders. Spark has rights to a proprietary manufacturing platform that has an unparalleled track record of success in supporting clinical studies across diverse therapeutic areas and routes of administration. The company's expertise across research, clinical, regulatory and manufacturing builds on a legacy of innovation and excellence in gene therapy established by Spark's team while at The Children's Hospital of Philadelphia Center for Cellular and Molecular Therapeutics. To learn more visit www.sparktx.com.

Media Inquiries:
Jessica Rowlands
202-729-4089
Jessica.Rowlands@fkhealth.com


'/>"/>
SOURCE Spark Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Snoring Therapy Awarded The Prestigious Spark Award
2. Kalyspo Awarded Best of Ann Arbor SPARK Boot Camp
3. Next Generation Sequencing Bioinformatics Heats up: Nearing $1000 Genome Sparks Soaring Data Output
4. Spark Therapeutics to Present at 32nd Annual J.P. Morgan Healthcare Conference
5. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
6. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
9. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Research and Markets  has announced the addition of ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... needle commonly used with a syringe to inject substances ... it. A hypodermic needle is used for rapid delivery ... ingested. Hypodermic needles are broadly classified into non-safety and ...
(Date:7/11/2014)... July 11, 2014 According to ... "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization ... and Forecast, 2013-2019" the global endoscopy devices market was ... expected to grow at a CAGR of 6.8% from ... USD 36.9 billion in 2019. Browse the ...
(Date:7/11/2014)... DIEGO , July 11, 2014 Neurelis, ... Corp. ("Biotie") to end the option held by Biotie ... commence further development of NRL-1 (intranasal diazepam) for pediatric ... Over the past year, Biotie has advanced ... in preparation for the pivotal clinical work required for ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... September 30, 2011. "We are focused on ... complete response letter around year-end and filing the lorcaserin ... the first half of next year," stated Jack Lief, ...
... China Kanghui Holdings (NYSE: KH ) ("Kanghui" or ... orthopedic implants in China, today announced financial results for the ... Highlights Total net revenue for the third ... from RMB63.6 million in the corresponding period of ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 2Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 3Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 4Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 5Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 6Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 7Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 8China Kanghui Holdings Reports Third Quarter 2011 Financial Results 2China Kanghui Holdings Reports Third Quarter 2011 Financial Results 3China Kanghui Holdings Reports Third Quarter 2011 Financial Results 4China Kanghui Holdings Reports Third Quarter 2011 Financial Results 5China Kanghui Holdings Reports Third Quarter 2011 Financial Results 6China Kanghui Holdings Reports Third Quarter 2011 Financial Results 7China Kanghui Holdings Reports Third Quarter 2011 Financial Results 8China Kanghui Holdings Reports Third Quarter 2011 Financial Results 9China Kanghui Holdings Reports Third Quarter 2011 Financial Results 10China Kanghui Holdings Reports Third Quarter 2011 Financial Results 11China Kanghui Holdings Reports Third Quarter 2011 Financial Results 12China Kanghui Holdings Reports Third Quarter 2011 Financial Results 13China Kanghui Holdings Reports Third Quarter 2011 Financial Results 14
(Date:7/13/2014)... treatment and variations in the quality of care are ... patients still varies widely between regions within Europe, according ... adults to date, published in The Lancet Oncology ... for most cancers of the blood has increased over ... of new targeted drugs in the early 2000s such ...
(Date:7/13/2014)... type-1 diabetes could improve patient care worldwide and ... the device,s inventors at the Stanford University School ... be published online July 13 in Nature ... type-1 diabetes outside hospital settings. The handheld microchips ... mellitus, which are both characterized by high blood-sugar ...
(Date:7/13/2014)... irrigation systems are mainly utilized for agriculture in order ... maintain soil quality. The application of micro irrigation systems ... generator for manufacturers in future. The trend of utilizing ... to the adoption of micro irrigation techniques for agriculture, ... for micro irrigation systems, as they reduce the overall ...
(Date:7/13/2014)... MarketsandMarkets recently conducted a study on the ... rendering; Layout and Animation; Image Reconstruction]: Global Advancements, ... analyzes and studies the major market drivers, restraints, ... Europe, Middle East and Africa, Asia-Pacific and Latin ... of the 3D imaging market, providing an in-depth ...
(Date:7/13/2014)... The federal court overseeing thousands of ... against Johnson & Johnson’s Ethicon, Inc. is preparing to ... to get underway next month. According to an Amended ... Southern District of West Virginia on July 9, 2014, ... 2014 at 3:00 p.m. July selection is slated to ...
Breaking Medicine News(10 mins):Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4
... an approved clot-busting drug remains the most beneficial proven ... ,The Guidelines for the Early Management ... options – such as intra-arterial administration of clot-busting drugs ... ,The guidelines focus on the crucial ...
... may hold the key to not only stopping heart ... ever occurring//. Researchers at Mount Sinai School of Medicine ... with a novel contrast agent know as N1177 can ... stroke. The findings may help physicians diagnosis a heart ...
... resistance after the failure of an anti-HIV drug combination is ... cell losses, according to a study of patients failing treatment ... the study also found that on average, patients who remained ... choice still available to them for every six months on ...
... special envoy for the fight against tuberculosis, on Tuesday called ... the spread of TB and HIV in Africa.// ... that the two diseases are spreading rapidly across the continent ... assistance. "We are providing antiretrovirals to as many people as ...
... has evolved to become resistant to all classes of antibiotics ... U.S. Centers for Disease Control and Prevention (CDC) has said ... due to the emergence of drug-resistant strains in ... remains as there is no indication so far that the ...
... - artificial legs made in Rajasthan - is all set to ... ,Experts from the Bhagwan Mahaveer Viklang Sahayta Samiti (BMVSS) ... Indian contingent of the UN peacekeeping force in Lebanon, BMVSS general ... a camp in Lebanon April 14 to 25. Five technicians would ...
Cached Medicine News:Health News:Intravenous Delivery of Clot-busting Drug Still Best Intervention for Ischemic Stroke 2Health News:CT Imaging With Novel Contrast Agent May Predict Heart Attack in Waiting 2Health News:Is There Any Clinical Benefit to Staying on a Failing Regimen? 2Health News:Is There Any Clinical Benefit to Staying on a Failing Regimen? 3Health News:Jaipur Foot Takes Off for Lebanon 2
Bi-angled insertion jaws designed to enhance surgeon comfort and efficiency. Reverse action releases lens when handle is compressed. Made in titanium....
45 degree. Angled shafts. Tip to angle length: 11.5 mm. Stops in handle designed to prevent "over folding". Manufactured in titanium....
Curved shafts with serrated 1.5 mm upper and 2 mm lower jaws. Serrated cross action handle with slide lock and polished finish. Most popular size or model....
A gently curved forceps designed to easily fold today's soft intraocular lenses. The serrated handle ensures a firm grip throughout the folding procedure....
Medicine Products: